Experience

Microvioma

• India
• Biotechnology Research
• 1 - 100 Employee

• Chief Executive Officer

  • Aug 2022 - Present

  Founded Microvioma - a research-based Organization founded in verified science to participate in WHO's One Health mission by providing microbiology-based solutions (www.microvioma.com). Founded Microvioma - a research-based Organization founded in verified science to participate in WHO's One Health mission by providing microbiology-based solutions (www.microvioma.com).



Orchid Pharma

• India
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Scientific Advisor (Head of New Drug Discovery AI & Project Management)

  • May 2013 - Present

  Scientific Advisor for New Drug Discovery Programs (Biology) & Project Management As Scientific Advisor, I head the Anti-infectives (Biology) Drug Discovery Research program & Project Management; and continue in the Leadership role for all the other discovery programs. Engaged in Business Development activities of NDD Assets.

• Associate Director (R&D)

  • Apr 2010 - Apr 2013

  Lead Proprietary & Collaborative anti-infective new drug discovery biology (incl. Design, Execution and Delivery); provide core expertise support to API, NDDS, Regulatory, Anti-infective product management activities. I delivered one candidate that’s out licensed to Allecra Therapeutics, and had completed phase 3 Clinical Trials in early 2020

• Chief Research Scientist

  • Apr 2008 - Mar 2010

  Led the division of Anti-infectives Biology team in the discovery of novel antimicrobials

• Senior Research Scientist

  • Jul 2006 - Mar 2008

  Preclinical Discovery of Anti-infective NCEs



CYMBIOTICS BIOPHARMA PRIVATE LIMITED

• India
• Hospitals and Health Care
• 1 - 100 Employee

• Chief Scientific Officer

  • Jun 2023 - Present

  Driving business strategy, and Mentor Skin and Cosmetics R&D Driving business strategy, and Mentor Skin and Cosmetics R&D



Anabio.in

• India
• Manufacturing
• 1 - 100 Employee

• Scientific Advisor

  • Jun 2020 - Present

  Microbiological Testing and Contract Research Services Advisor Microbiological Testing and Contract Research Services Advisor



Acharya Institutes

• India
• Higher Education
• 300 - 400 Employee

• Vice-Chancellor-Designate of the Proposed Acharya University

  • Aug 2021 - Jul 2022

  Additional responsibility: Designated as the Vice-Chancellor of Proposed Acharya University by the Governing Board for initial setting up of the University. Set up an eminent Governing Board and steered the development of initial processes for starting the University.

• Campus Director

  • Feb 2018 - Jul 2022

  Started out at Professor of Biological Sciences (1y 02/2018) and elevated to Director of R&D Directorate (08/2019) and finally as the Campus Director in Aug 2020. The vision for Acharya is to be an academic campus of excellence as a fountainhead of value-based creativity for transformative societal impact. Promoting Faculty & Student Centric education with a focus on trans-disciplinary research in the transformation from the grassroots level to futuristic research. Looking beyond… Show more Started out at Professor of Biological Sciences (1y 02/2018) and elevated to Director of R&D Directorate (08/2019) and finally as the Campus Director in Aug 2020. The vision for Acharya is to be an academic campus of excellence as a fountainhead of value-based creativity for transformative societal impact. Promoting Faculty & Student Centric education with a focus on trans-disciplinary research in the transformation from the grassroots level to futuristic research. Looking beyond one's academic qualifications and /or experience leads to liberal brain-storming of ideas with experts of unrelated fields to kindle innovation! This is possible at Acharya Institutes consisting of 15 institutions spread across disciplines of Health, Engineering, Design, Art, Socio-political sciences, skill-development, etc. I promote & facilitate Trans-disciplinary Research across these and bridge geographic or scientific boundaries across the campus.



FDA

• United States
• Government Administration
• 700 & Above Employee

• US FDA ORISE Fellow

  • 2005 - Jul 2006

  At CBER US FDA I developed an in vitro model for safety evaluation of meningococcal vaccines Funding: Oak Ridge Institute for Science and Education I am officially trained by the FDA as a Reviewer of Applications; and trained by the NIH in rodent techniques At CBER US FDA I developed an in vitro model for safety evaluation of meningococcal vaccines Funding: Oak Ridge Institute for Science and Education I am officially trained by the FDA as a Reviewer of Applications; and trained by the NIH in rodent techniques



Johns Hopkins Medicine

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Johns Hopkins Medical Institutions Post-Doctoral Fellow

  • Nov 2003 - Sep 2005

  Worked with in vitro and in vivo neonatal rat Human blood-brain barrier (BBB) model in relation to E. coli neonatal meningitis. Authored/Co-authored 10 peer-reviewed publications and 06 Conference Proceedings • Understood the host-bacterial interactions and the ability of E. coli K1 to cross the BBB, its tropism to BBB by dissecting the pathogenicity islands • Studied the association, invasion, and transcytosis of E. coli, M. tuberculosis, and C. neoformans at the BBB Worked with in vitro and in vivo neonatal rat Human blood-brain barrier (BBB) model in relation to E. coli neonatal meningitis. Authored/Co-authored 10 peer-reviewed publications and 06 Conference Proceedings • Understood the host-bacterial interactions and the ability of E. coli K1 to cross the BBB, its tropism to BBB by dissecting the pathogenicity islands • Studied the association, invasion, and transcytosis of E. coli, M. tuberculosis, and C. neoformans at the BBB



Umeå University

• Sweden
• Higher Education
• 700 & Above Employee

• Umeå Universitet Post-Doctoral Fellow

  • Jan 2002 - Nov 2003

  Identified and characterized the Peptidoglycan-associated lipoprotein with amyloid nature from A. actinomycetemcomitans (AA). The model organism was Aa to study molecular mimicry • Since AA EM showed a fibrillar structure, morphologically similar to E. coli Curli, I investigated it using E. coli anti-curli antibodies (from Staffan Normark's group), and found a cross-reacting protein of the same size in AA. I identified this protein as “AA-peptidoglycan associated lipoprotein”, and… Show more Identified and characterized the Peptidoglycan-associated lipoprotein with amyloid nature from A. actinomycetemcomitans (AA). The model organism was Aa to study molecular mimicry • Since AA EM showed a fibrillar structure, morphologically similar to E. coli Curli, I investigated it using E. coli anti-curli antibodies (from Staffan Normark's group), and found a cross-reacting protein of the same size in AA. I identified this protein as “AA-peptidoglycan associated lipoprotein”, and characterized it by raising antibodies, 2D-GE, N-terminal sequencing, MALDI-TOF and MS/MS (some done at Core facilities); did classical amyloid assays, IEM and Atomic force microscopy • Studied the host-bacteria interaction on the endothelial cells and arterial tissue by competitive inhibition, in situ FIA, basic proteomics, adhesion and invasion assays Show less Identified and characterized the Peptidoglycan-associated lipoprotein with amyloid nature from A. actinomycetemcomitans (AA). The model organism was Aa to study molecular mimicry • Since AA EM showed a fibrillar structure, morphologically similar to E. coli Curli, I investigated it using E. coli anti-curli antibodies (from Staffan Normark's group), and found a cross-reacting protein of the same size in AA. I identified this protein as “AA-peptidoglycan associated lipoprotein”, and… Show more Identified and characterized the Peptidoglycan-associated lipoprotein with amyloid nature from A. actinomycetemcomitans (AA). The model organism was Aa to study molecular mimicry • Since AA EM showed a fibrillar structure, morphologically similar to E. coli Curli, I investigated it using E. coli anti-curli antibodies (from Staffan Normark's group), and found a cross-reacting protein of the same size in AA. I identified this protein as “AA-peptidoglycan associated lipoprotein”, and characterized it by raising antibodies, 2D-GE, N-terminal sequencing, MALDI-TOF and MS/MS (some done at Core facilities); did classical amyloid assays, IEM and Atomic force microscopy • Studied the host-bacteria interaction on the endothelial cells and arterial tissue by competitive inhibition, in situ FIA, basic proteomics, adhesion and invasion assays Show less



Dr Reddy's Foundation

• Non-profit Organizations
• 500 - 600 Employee

• Industry RA

  • Dec 2000 - Dec 2001

  Involved in New Drug Discovery program of Antiinfectives project on Oxazolidinones. Was the key co-inventor of DRF 8417 Involved in New Drug Discovery program of Antiinfectives project on Oxazolidinones. Was the key co-inventor of DRF 8417



Bengaluru

• Bengaluru, Karnataka, India

• Clinical Microbiologist

  • Dec 1993 - Sep 1997

  Consulting Clinical Microbiologist at 07 hospital laboratories and full time Microbiologist / lecturer at KIMS Hospital & Research Cebtre, Bangalore. Consulting Clinical Microbiologist at 07 hospital laboratories and full time Microbiologist / lecturer at KIMS Hospital & Research Cebtre, Bangalore.